Takeda Pharmaceutical (4502.T) Profit Metrics
Price: $4540.00
Market Cap: $7.20T
Avg Volume: 4.11M
Market Cap: $7.20T
Avg Volume: 4.11M
Country: JP
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Profit Metrics Summary (Annual)
According to Takeda Pharmaceutical's latest annual financial reports:
- The company has reported a gross profit of 2.83T, indicating the amount earned after deducting the cost of goods sold (COGS) from revenue. The gross profit margin is 66.43%, with a year-over-year growth of 1.76%.
- Takeda Pharmaceutical's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 874.60B. The EBITDA margin stands at 20.51%, showing a growth of -26.16% compared to the previous year.
- The operating income, representing the profit from business operations before taxes and interest, stands at 214.07B. The operating margin is 5.02%, with a year-over-year growth of -56.36%.
- The net income, which shows the company's total earnings or profit after all expenses, is 144.07B. The net profit margin is 3.38%, demonstrating a growth of -54.56% from the previous year.
These metrics provide a comprehensive overview of Takeda Pharmaceutical's profitability and operational efficiency over the past year.
Gross Profit
$2.83T
Gross Profit Margin (2023)
66.43%
EBITDA
$874.60B
EBITDA Margin
20.51%
Operating Income (2023)
$214.07B
Operating Margin
5.02%
Net Income
$144.07B
Net Profit Margin
3.38%
Historical Gross Profit
Historical Gross Profit Margin
Historical Gross Profit Growth
Historical EBITDA
Historical EBITDA Margin
Historical EBITDA Growth
Historical Operating Income
Historical Operating Profit Margin
Historical Operating Income Growth
Historical Net Income
Historical Net Profit Margin
Historical Net Income Growth
Takeda Pharmaceutical Historical Profit Metrics
Takeda Pharmaceutical Historical Profits
The table below shows various profit metrics for each year, with the latest data available for the last fiscal year 2023.
| Year | Gross Profit | Gross Profit Growth | Operating Income | Operating Income Growth | Net Income | Net Income Growth | EBITDA | EBITDA Growth |
|---|---|---|---|---|---|---|---|---|
| 2023 | $2.83T | 1.76% | $214.07B | -56.36% | $144.07B | -54.56% | $874.60B | -26.16% |
| 2022 | $2.78T | 13.05% | $490.50B | 6.44% | $317.02B | 37.80% | $1.18T | 0.11% |
| 2021 | $2.46T | 11.74% | $460.84B | -9.51% | $230.06B | -38.81% | $1.18T | 20.28% |
| 2020 | $2.20T | 0.09% | $509.27B | 407.20% | $376.00B | 749.90% | $983.72B | 11.74% |
| 2019 | $2.20T | 53.14% | $100.41B | -51.01% | $44.24B | -59.46% | $880.33B | 89.64% |
| 2018 | $1.44T | 12.78% | $204.97B | -15.23% | $109.13B | -41.61% | $464.22B | 28.96% |
| 2017 | $1.27T | 8.63% | $241.79B | 55.13% | $186.89B | 62.59% | $359.96B | 21.25% |
| 2016 | $1.17T | -7.76% | $155.87B | 19.14% | $114.94B | 43.38% | $296.88B | -15.14% |
| 2015 | $1.27T | 1.20% | $130.83B | 201.22% | $80.17B | 154.99% | $349.85B | 510.70% |
| 2014 | $1.26T | 4.61% | $-129.25B | -192.81% | $-145.78B | -236.68% | $57.29B | -84.44% |
| 2013 | $1.20T | 8.27% | $139.27B | 13.69% | $106.66B | -18.73% | $368.18B | 4.84% |
| 2012 | $1.11T | 3.15% | $122.50B | -53.78% | $131.24B | 5.70% | $351.18B | -13.19% |
| 2011 | $1.08T | -2.37% | $265.03B | -27.80% | $124.16B | -49.91% | $404.56B | -15.65% |
| 2010 | $1.10T | -6.70% | $367.08B | -12.64% | $247.87B | -16.75% | $479.63B | -9.86% |
| 2009 | $1.18T | -5.44% | $420.21B | 37.11% | $297.74B | 27.03% | $532.08B | 2.67% |
| 2008 | $1.25T | 13.92% | $306.47B | -27.57% | $234.38B | -34.06% | $518.25B | -14.88% |
| 2007 | $1.10T | 6.89% | $423.12B | -7.72% | $355.45B | 5.85% | $608.87B | -6.96% |
| 2006 | $1.03T | 10.26% | $458.50B | 13.83% | $335.81B | 7.20% | $654.45B | 19.63% |
| 2005 | $930.11B | 10.23% | $402.81B | 4.55% | $313.25B | 12.91% | $547.05B | 15.74% |
| 2004 | $843.78B | 3.27% | $385.28B | 3.67% | $277.44B | -2.74% | $472.66B | -0.41% |
Related Metrics
Explore detailed financial metrics and analysis for 4502.T.